<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6442">
  <stage>Registered</stage>
  <submitdate>5/04/2017</submitdate>
  <approvaldate>5/04/2017</approvaldate>
  <nctid>NCT03130959</nctid>
  <trial_identification>
    <studytitle>An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies</studytitle>
    <scientifictitle>Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Subjects With High Grade Primary CNS Malignancies</scientifictitle>
    <utrn />
    <trialacronym>CheckMate 908</trialacronym>
    <secondaryid>2016-004441-82</secondaryid>
    <secondaryid>CA209-908</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Various Advanced Cancer</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - Nivolumab
Other interventions - Ipilimumab

Experimental: Module A - nivolumab

Experimental: Module B - nivolumab plus ipilimumab


Other interventions: Nivolumab
Specified dose on specified day

Other interventions: Ipilimumab
Specified dose on specified day

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of dose limiting toxicity (DLT) - Safety and tolerability</outcome>
      <timepoint>Approximately 6 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of serious adverse events (SAEs) - Safety and tolerability</outcome>
      <timepoint>Approximately 6 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of adverse events (AEs) - Safety and tolerability</outcome>
      <timepoint>Approximately 6 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Overall Survival (OS) - Diffuse Intrinsic Pontine Glioma (DIPG).</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Progression Free Survival (PFS) - All other tumor types.</outcome>
      <timepoint>Approximately 2 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of AEs - Safety</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of SAEs - Safety</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of laboratory abnormalities - Safety</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival (PFS) - Diffuse Intrinsic Pontine Glioma (DIPG)</outcome>
      <timepoint>18 months to 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival - Diffuse Intrinsic Pontine Glioma (DIPG). Overall Survival at 12 month point (OS(12)).</outcome>
      <timepoint>Approximately 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival - High Grade Glioma (HGG), Medulloblastoma, Ependymoma, and other high-grade CNS tumors. At 6 months (PFS(6)).</outcome>
      <timepoint>Approximately 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS) - High Grade Glioma (HGG), Medulloblastoma, Ependymoma, and other high-grade CNS tumors.</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival - High Grade Glioma (HGG), Medulloblastoma, Ependymoma. At 12 month point (OS(12)).</outcome>
      <timepoint>Approximately 12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

          -  Children and adolescents diagnosed with either:

          -  Diffuse Intrinsic Pontine Glioma (DIPG)

          -  High Grade Glioma (HGG)

          -  Medulloblastoma

          -  Ependymoma

          -  Other high-grade tumors of the central nervous system

          -  Lansky play score (LPS) for =&lt; 16 years of age or Karnofsky performance scale (KPS)
             for &gt; 16 years of age assessed within two weeks of enrollment must be &gt;= 60

          -  A tumor sample must be available for submission to central laboratory [not required
             for DIPG]</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>21</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Participants with active, known or suspected autoimmune disease

          -  Participants unable to taper steroids due to ongoing mass effect

          -  Participants with low-grade gliomas or tumors of unknown malignant potential

          -  Prior treatment with any drug that targets T cell co-stimulation pathways (such as
             checkpoint inhibitors)

        Other protocol defined inclusion/exclusion criteria could apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>6/06/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>170</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>15/06/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>Local Institution - Randwick</hospital>
    <hospital>Local Institution - Sth Brisbane</hospital>
    <hospital>Local Institution - Clayton</hospital>
    <hospital>Local Institution - Parkville</hospital>
    <hospital>Local Institution - Subiaco</hospital>
    <postcode>2031 - Randwick</postcode>
    <postcode>4101 - Sth Brisbane</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3052 - Parkville</postcode>
    <postcode>6008 - Subiaco</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Parana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio Grande Do Sul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Angers</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre les Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>VIillejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Wuerzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Esplugues de Llobregat</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Greater London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Merseyside</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Tyne and Wear</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the safety and effectiveness of nivolumab alone and
      in combination with ipilimumab in pediatric patients with high grade primary central nervous
      system (CNS) malignancies</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03130959</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</name>
      <address />
      <phone>please email:</phone>
      <fax />
      <email>Clinical.Trials@bms.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>